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The efavirenz pharmacokinetic raw data presented in this article
was obtained in an average bioequivalence study between a local
brand and Stocrin (Merck Sharp & Dohme, purchased from Aus-
tralia, batch H009175, expiration date November 2013). Dose was
administered at night (9:00 p.m.) two hours after food intake.
Fourteen healthy subjects, 8 women and 6 men, completed the
study. For each subject, 15 data points until 96 h post-
administration are included. Subject demographic characteristics
and sequences of administration are provided along with indivi-
dual pharmacokinetic proﬁles of efavirenz obtained for both for-
mulations after a single oral dose of 600 mg. This data provides
information in support of the research article “Sex-by-formulation
interaction assessed through a bioequivalence study of efavirenz
tablets” [1].
& 2016 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).vier Inc. This is an open access article under the CC BY license
/j.ejps.2016.02.001
).
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acquiredHigh performance liquid chromatography with ultraviolet detectionata format Raw
xperimental
factorsBlood plasma samples were processed for efavirenz extraction and quantiﬁcation
as described elsewhere [1]xperimental
featuresA 2-treatment, 2-period, 2-sequence, randomized and balanced crossover design
was carried out with 14 healthy subjects, 8 women and 6 menata source
locationMontevideo, Uruguayata accessibility Data supplied with this articleD
Value of the data
 Efavirenz pharmacokinetic data with intensive sampling obtained after nightly dosing. Char-
acterization of efavirenz pharmacokinetics after single oral nightly dose can be performed with this
data. Efavirenz chronopharmacokinetics and evaluation of daytime administration on bioequiva-
lence can be studied by comparison with standard bioequivalence trials.
 Comparison of Reference (Stocrins, Merck Sharp & Dohme) performance in different populations.
Data collected for the Reference formulation could be managed with the objective of comparing its
performance in different populations.
 Development of in vitro–in vivo correlations. Efavirenz is classiﬁed as Class II drug in the Bio-
pharmaceutical Classiﬁcation System (BCS), its oral absorption is limited by its dissolution.
Appropriate in vitro assays could help to explain and predict dosage bioavailability.1. Data
In this article, raw pharmacokinetic data obtained in an efavirenz average bioequivalence study carried
out on 14 healthy subjects is presented. Venous plasma efavirenz concentrations were obtained after a
600 mg oral dose of a local brand (Test) and the Reference, Stocrin (Merck Sharp & Dohme).2. Experimental design, materials and methods
A randomized two-treatment, two-period, two-sequence, single-dose crossover study with a
washout period of 28 days was performed for bioequivalence evaluation of Test formulation. Sixteen
healthy Caucasian subjects were initially recruited, 8 males and 8 females. Dose (600 mg) was
administered at night (9:00 p.m.) two hours after the intake of a standardized dinner. Blood samples
were obtained up to 96 h post-dosing. Efavirenz concentrations were measured in venous plasma by
high performance liquid chromatography with UV detection at 205 nm (HPLC-UV), using a validated
analytical method with a lower limit of quantiﬁcation of 50 ng/mL. Detailed information regarding
this method was previously described [1]. The study protocol followed the tenets of the Declaration of
Helsinki adopted by the World Medical Association in 1964 and its successive amendments, being
previously approved by the Institutional Ethics Review Committee of the Faculty of Chemistry –
Universidad de la República. All volunteers received a leaﬂet with study details and efavirenz
Table 1
Subject demographic characteristics.
Subject IDS Sex Weight (kg) Age (years) Height (cm) Smoker statusa Sequence of administrationb
1 Female 66 49 165 NS RT
2 Female 70 37 170 NS RT
3 Female 70 20 164 NS TR
4 Female 56 19 160 NS TR
5 Female 61 20 168 NS TR
6 Female 60 20 160 S RT
7 Female 63 26 161 NS RT
8 Female 65 35 174 S TR
9 Male 85 35 184 S RT
10 Male 93 28 181 NS RT
11 Male 74 23 181 NS TR
12 Male 76 20 174 NS TR
13 Male 106 46 167 S TR
14 Male 110 22 181 NS RT
15 Male 74 18 173 NS TR
16 Male 70 49 165 NS RT
a NS: non-smoker; S: smoker.
b TR: Test-Reference; RT: Reference-Test.
Fig. 1. Individual efavirenz plasma concentration–time proﬁles after the administration of Test and Reference formulations.
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demographic characteristics of participating volunteers, along with the assigned sequence of product
administration. Fourteen volunteers ﬁnished the study. Subject 16 did not show up the ﬁrst day of the
study. Subject 11 presented rash after administration of Test formulation. Fortunately, both indivi-
duals belonged to different sequence of administration, and so replacement was not necessary to
maintain the crossover balanced.
Fig. 2. Individual efavirenz plasma concentration–time proﬁles (log-linear scale) after the administration of Test and Reference
formulations.
M. Ibarra et al. / Data in Brief 7 (2016) 751–754754Pharmacokinetic data of efavirenz after single oral dose of Test and Reference is presented in
Figs. 1 and 2. For subject 11, only Test data is available. Individual efavirenz plasma concentration from
both formulations could be retrieved from a previously published article [2].Acknowledgements
In vivo data was taken from a study funded by Servimedic Laboratory, Uruguay.Appendix A. Supplementary material
Supplementary data associated with this article can be found in the online version at http://dx.doi.
org/10.1016/j.dib.2016.03.036.References
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